Drug Profile
Research programme: PPAR agonists - Merck & Co
Latest Information Update: 30 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Benzimidazoles; Benzopyrans; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
- Discontinued Hyperlipidaemia
Most Recent Events
- 30 Aug 2011 Discontinued - Preclinical for Hyperlipidaemia in USA (PO)
- 30 Aug 2011 No development reported for Type-2 diabetes mellitus in USA (PO)
- 10 Apr 2008 Research phase development is ongoing for Diabetes